A Novel NHE1-Centered Signaling Cassette Drives Epidermal Growth Factor Receptor–Dependent Pancreatic Tumor Metastasis and Is a Target for Combination Therapy

Neoplasia (United States)

Volumn 17, Issue 2, 2015, Pages 155-166

  Cardone, Rosa Angela ^a   Greco, Maria Raffaella ^a   Zeeberg, Katrine ^a   Zaccagnino, Angela ^b   Saccomano, Mara ^c   Bellizzi, Antonia ^a   Bruns, Philipp ^d   Menga, Marta ^a   Pilarsky, Christian ^e   Schwab, Albrecht ^d   Alves, Frauke ^c   Kalthoff, Holger ^b   Casavola, Valeria ^a,f   Reshkin, Stephan Joel ^a,f  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF KIEL   (Germany)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f Center of Excellence in Genomics (CEGBA)   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; SCAFFOLD PROTEIN; SODIUM PROTON EXCHANGE PROTEIN 1; ANTIARRHYTHMIC AGENT; CARIPORIDE; CATION TRANSPORT PROTEIN; ERLOTINIB; GUANIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SLC9A1 PROTEIN, HUMAN; SODIUM PROTON EXCHANGE PROTEIN; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLONY FORMATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LIPID MEMBRANE; LIPID RAFT; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; CELL LINE; COMBINATION DRUG THERAPY; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; SCID MOUSE; SECONDARY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CATION TRANSPORT PROTEINS; CELL LINE; CELL LINE, TUMOR; DRUG THERAPY, COMBINATION; ERLOTINIB HYDROCHLORIDE; GUANIDINES; HUMANS; MICE; MICE, NUDE; MICE, SCID; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SODIUM-HYDROGEN ANTIPORTER; SULFONES;

EID: 84989332195     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.12.003     Document Type: Article

References (45)

1. [1] Kleger, A, Perkhofer, L, Seufferlein, T, Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol 00 (2014), 1–11, 10.1093/annonc/mdu013.
2. [2] Rhim, AD, Mirek, ET, Aiello, NM, Maitra, A, Bailey, JM, McAllister, F, Reichert, M, Beatty, GL, Rustgi, AK, Vonderheide, RH, et al. EMT and dissemination precede pancreatic tumor formation. Cell 148 (2012), 349–361.
3. [3] Yang, GY, Wagner, TD, Fuss, M, Thomas, CR Jr., Multimodality approaches for pancreatic cancer. CA Cancer J Clin 55 (2005), 352–367.
4. [4] Korc, M, Pancreatic cancer-associated stroma production. Am J Surg 194 (2007), S84–S86.
5. [5] Ouyang, H, Gore, J, Deitz, S, Korc, M, microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-beta actions. Oncogene 33 (2013), 4664–4674.
6. [6] Arlt, A, Muerkoster, SS, Schafer, H, Targeting apoptosis pathways in pancreatic cancer. Cancer Lett 332 (2013), 346–358.
7. [7] Oliveira-Cunha, M, Newman, WG, Siriwardena, AK, Epidermal growth factor receptor in pancreatic cancer. Cancers (Basel) 3 (2011), 1513–1526.
8. [8] Walters, DM, Lindberg, JM, Adair, SJ, Newhook, TE, Cowan, CR, Stokes, JB, Borgman, CA, Stelow, EB, Lowrey, BT, Chopivsky, ME, et al. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia 15 (2013), 143–155.
9. [9] Collisson, EA, Sadanandam, A, Olson, P, Gibb, WJ, Truitt, M, Gu, S, Cooc, J, Weinkle, J, Kim, GE, Jakkula, L, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17 (2011), 500–503.
10. [10] Siveke, JT, Crawford, HC, KRAS above and beyond—EGFR in pancreatic cancer. Oncotarget 3 (2012), 1262–1263.
11. [11] Ardito, CM, Gruner, BM, Takeuchi, KK, Lubeseder-Martellato, C, Teichmann, N, Mazur, PK, Delgiorno, KE, Carpenter, ES, Halbrook, CJ, Hall, JC, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22 (2012), 304–317.
12. [12] Navas, C, Hernandez-Porras, I, Schuhmacher, AJ, Sibilia, M, Guerra, C, Barbacid, M, EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22 (2012), 318–330.
13. [13] Vickers, MM, Powell, ED, Asmis, TR, Jonker, DJ, Hilton, JF, O'Callaghan, CJ, Tu, D, Parulekar, W, Moore, MJ, Comorbidity, age and overall survival in patients with advanced pancreatic cancer—results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer 48 (2012), 1434–1442.
14. [14] Yao, W, Feng, D, Bian, W, Yang, L, Li, Y, Yang, Z, Xiong, Y, Zheng, J, Zhai, R, He, J, EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation. Amino Acids 43 (2012), 2027–2035.
15. [15] Clapéron, A, Guedj, N, Mergey, M, Vignjevic, D, Desbois-Mouthon, C, Boissan, M, Saubaméa, B, Paradis, V, Housset, C, Fouassier, L, Loss of EBP50 stimulates EGFR activity to induce EMT phenotypic 619 features in biliary cancer cells. Oncogene 31 (2012), 1376–1388.
16. [16] Reshkin, SJ, Cardone, RA, Harguindey, S, (2012). Na+−H + exchanger, pH regulation and cancer. Recent Pat Anticancer Drug Discov 8 (2013), 85–99.
17. [17] Reshkin, SJ, Bellizzi, A, Cardone, RA, Tommasino, M, Casavola, V, Paradiso, A, Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na +/H + exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res 9 (2003), 2366–2373.
18. [18] Gupta, SC, Sung, B, Prasad, S, Webb, LJ, Aggarwal, BB, Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 34 (2013), 508–517.
19. [19] Pilarsky, C, Ammerpohl, O, Sipos, B, Dahl, E, Hartmann, A, Wellmann, A, Braunschweig, T, Löhr, M, Jesenofsky, R, Friess, H, et al. Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med 12 (2008), 2823–2835.
20. [20] Chou, TC, Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70 (2010), 440–446.
21. [21] Alves, F, Contag, S, Missbach, M, Kaspareit, J, Nebendahl, K, Borchers, U, Heidrich, B, Streich, R, Hiddemann, W, An orthotopic model of ductal adenocarcinoma of the pancreas in severe combined immunodeficient mice representing all steps of the metastatic cascade. Pancreas 23 (2001), 227–235.
22. [22] Egberts, JH, Schniewind, B, Sipos, B, Hinz, S, Kalthoff, H, Tepel, J, Superiority of extended neoadjuvant chemotherapy with gemcitabine in pancreatic cancer: a comparative analysis in a clinically adapted orthotopic xenotransplantation model in SCID beige mice. Cancer Biol Ther 6 (2007), 1227–1232.
23. [23] Cardone, RA, Casavola, V, Reshkin, SJ, The role of disturbed pH dynamics and the Na +/H + exchanger in metastasis. Nat Rev Cancer 5 (2005), 786–795.
24. [24] Busco, G, Cardone, RA, Greco, MR, Bellizzi, A, Colella, M, Antelmi, E, Mancini, MT, Dell'Aquila, ME, Casavola, V, Paradiso, A, et al. NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space. FASEB J 24 (2010), 3903–3915.
25. [25] Kimlin, L, Kassis, J, Virado, V, 3D in vitro tissue models and their potential for drug screening. Exp Opin Drug Discov 8 (2013), 1455–1466.
26. [26] Tong, Z, Chakraborty, S, Sung, B, Koolwal, P, Kaur, S, Aggarwal, BB, Mani, SA, Bresalier, RS, Batra, SK, Guha, S, Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells. Cancer, 117, 2010.
27. [27] Stock, C, Ludwig, FT, Schwab, A, Is the multifunctional Na(+)/H(+) exchanger isoform 1 a potential therapeutic target in cancer?. Curr Med Chem 19 (2012), 647–660.
28. [28] Bravo-Cordero, JJ, Hodgson, L, Condeelis, J, Directed cell invasion and migration during metastasis. Curr Opin Cell Biol 24 (2012), 277–283.
29. [29] Brisson, L, Reshkin, SJ, Gore, J, Roger, S, pH regulators in invadosomal functioning: proton delivery for matrix tasting. Eur J Cell Biol 91 (2012), 847–860.
30. [30] Vahle, AK, Domikowsky, B, Schwoppe, C, Krahling, H, Mally, S, Schafers, M, Hermann, S, Shahin, V, Haier, J, Schwab, A, et al. Extracellular matrix composition and interstitial pH modulate NHE1-mediated melanoma cell motility. Int J Oncol 44 (2014), 78–90.
31. [31] Cardone, RA, Bellizzi, A, Busco, G, Weinman, EJ, Dell'Aquila, ME, Casavola, V, Azzariti, A, Mangia, A, Paradiso, A, Reshkin, SJ, The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 18 (2007), 1768–1780.
32. [32] Accardi, R, Rubino, R, Scalise, M, Gheit, T, Shahzad, N, Thomas, M, Banks, L, Indiveri, C, Sylla, BS, Cardone, RA, et al. E6 and E7 from human papillomavirus type 16 cooperate to target the PDZ protein Na/H exchange regulatory factor 1. J Virol 85 (2011), 8208–8216.
33. [33] Good, MC, Zalatan, JG, Lim, WA, Scaffold proteins: hubs for controlling the flow of cellular information. Science 332 (2011), 680–686.
34. [34] Echarri, A, Del Pozo, MA, Caveolae. Curr Biol 22 (2012), R114–R116.
35. [35] Klinger, B, Sieber, A, Fritsche-Guenther, R, Witzel, F, Berry, L, Schumacher, D, Yan, Y, Durek, P, Merchant, M, Schafer, R, et al. Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol Syst Biol, 9, 2013, 673.
36. [36] Diep, CH, Munoz, RM, Choudhary, A, Von Hoff, DD, Han, H, Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res 17 (2011), 2744–2756.
37. [37] Jones, S, Rappoport, JZ, Interdependent epidermal growth factor receptor signalling and trafficking. Int J Biochem Cell Biol 51 (2014), 23–28.
38. [38] Han, W, Lo, HW, Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett 318 (2012), 124–134.
39. [39] Sigismund, S, Confalonieri, S, Ciliberto, A, Polo, S, Scita, G, Di Fiore, PP, Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol Rev 92 (2012), 273–366.
40. [40] Balbis, A, Posner, BI, Compartmentalization of EGFR in cellular membranes: role of membrane rafts. J Cell Biochem 109 (2010), 1103–1108.
41. [41] Irwin, ME, Mueller, KL, Bohin, N, Ge, Y, Boerner, JL, Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 226 (2011), 2316–2328.
42. [42] de Laurentiis, A, Donovan, L, Arcaro, A, Lipid rafts and caveolae in signaling by growth factor receptors. Open Biochem J 1 (2007), 12–32.
43. [43] Burke, P, Schooler, K, Wiley, HS, Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 12 (2001), 1897–1910.
44. [44] Sorkin, A, Von Zastrow, M, Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 3 (2002), 600–614.
45. [45] Yamamura, K, Kasuya, H, Sahin, TT, Tan, G, Hotta, Y, Tsurumaru, N, Fukuda, S, Kanda, M, Kobayashi, D, Tanaka, C, et al. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10. Ann Surg Oncol 21 (2013), 691–698.